Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Adjuvant nivolumab vs pembrolizumab in stage IIB/IIC melanoma: a reinforcement learning-based simulation study.
Perihan Perkin, Fahriye Tuğba Köş
Published: 202510.1007/s12094-025-04090-x
Abstract
BACKGROUND: Adjuvant programmed cell death protein 1 (PD-1) inhibitors (nivolumab, pembrolizumab) improve recurrence-free survival (RFS) in stage IIB-IIC melanoma, yet no head-to-head trial directly compares them. Traditional indirect methods estimat…
Preview only. Read the full abstract at the source